86 drugs will be "kicked out" of medical insurance!

This week, the State Food and Drug Administration released two batches of reference preparation catalogs, and 69 pharmaceutical companies had dishonesty behavior; the market changed drastically, 86 medicines were "kicked out" from medical insurance, and 221 medicines were included in Guangdong's "dual channel" catalog.
A large number of medicines Procurement "stopped"; new developments in centralized procurement, the results of centralized procurement of 50 drugs were released, and 45 drugs were included in mass procurement; new developments in research and development, domestic diabetes innovative drugs were approved, and two biological drugs welcomed the first domestically-owned company to declare; According to Qixin Information, Hengrui Pharmaceutical's performance has declined, and well-known pharmaceutical companies owed 2.
6 billion debts will change owners.
.
.
The major event in the pharmaceutical industry this week is exciting not to be missed!

TOP list in the week

TOP list in the week

Mine data

Mine data

Diabetes medication market has changed! Hausen's Class 1 new drug rose 600%

Nearly 2 billion sold in half a year, Qilu advances into the TOP20 brand

Domestic Class 1 new drugs broke out! Sales of 12 innovative drugs soared

Pharmaceutical company dynamics

Pharmaceutical company dynamics

8 pharmaceutical companies are amazing! Sichuan listed "Big Three" will train

89 pharmaceutical companies posted their third quarter transcripts! 26 doubled

Review drug news

Review drug news

Chia Tai Tianqing's biological drug blowout, 9 new drugs are expected to be launched

In the tens of billions of ophthalmic drugs market, Chengdu pharmaceutical companies struck class 2 new drugs

Yangtze River has made a breakthrough in proprietary Chinese medicine, and Class 1 new medicine is here again

$1.
9 billion anti-virus large variety! Chengdu Better Wins First Imitation

69 pharmaceutical companies were identified as "distrustful"

69 pharmaceutical companies were identified as "distrustful"

On October 21, the National Medical Insurance Administration disclosed in the "Responsible Comrades of the Medical Price and Bidding and Purchasing Guidance Center of the National Medical Security Administration Answering Questions about the Questions Related to the Credit Evaluation of Price Recruitment and Procurement".
"High amounts or large impacts of dishonesty were classified as "serious" dishonesty by the relevant provinces, and related pharmaceutical products were suspended from online purchases by the locals; 14 companies had dishonest behaviors such as giving "rebates", which were classified as "moderate" dishonesty according to the rules.
Pharmaceutical products were "brighted yellow", and the platform would give risk warnings when ordering purchases from medical institutions; 50 companies had relatively minor cases of dishonesty, which were classified as "general" dishonesty, and were reminded and cautioned
.

(National Medical Insurance Administration)

221 drugs included in Guangdong's "dual channel" catalog

221 drugs included in Guangdong's "dual channel" catalog

On October 19, the Guangdong Provincial Medical Insurance Bureau issued a notice to include 221 drugs in the scope of Guangdong's "dual channel" management drugs, including 162 Western medicines and 59 Chinese patent medicines
.

Up to now, some provinces such as Guangdong, Jiangsu, Anhui, Hunan, Hebei and other provinces have issued notices on the "dual-channel" management of drugs for national medical insurance negotiations

View:

View:

The "dual channel" policy will help promote the reform of the drug management system in medical institutions, improve the service quality of designated retail pharmacies for medical insurance, and solve the problem of "difficulty in entering the hospital" and "difficulty in landing" negotiated drugs, which can better meet the needs of the people for drug use
.

As the "dual channel" policy is successively implemented in various places, it is expected that the medical insurance negotiation drugs will further achieve a rapid increase in volume, and the market structure inside and outside the hospital may change

86 drugs will be "kicked out" of medical insurance

86 drugs will be "kicked out" of medical insurance

On October 18, the Shaanxi Provincial Medical Insurance Bureau announced the second batch of digestive lists of the original provincial supplementary drugs, involving 86 drugs.
The publicity date is October 18-22
.

In terms of drug types, there are 43 chemical drugs and proprietary Chinese medicines each; in terms of drug route, oral drugs are the main ones, and 21 are injections

Further reading:

Further reading:

Up to now, more than 20 places including Gansu, Ningxia, Xinjiang, Guangxi, Zhejiang, Shaanxi, Yunnan, Hunan, Jilin, Tianjin, Hebei, Anhui, Tibet, Beijing, Chongqing, Jiangsu, Qinghai, Sichuan, Henan, Shandong, Guizhou, etc.
have landed Implementation of the local supplement catalog recall policy
.

Performance decline! Hengrui Pharmaceutical meets the challenge

Performance decline! Hengrui Pharmaceutical meets the challenge

On October 20, Hengrui Medicine released its third-quarter report.
In the first three quarters, the company’s operating income was 20.
198 billion yuan, a year-on-year increase of 4.
05%; attributable net profit was 4.
207 billion yuan, a year-on-year decrease of 1.
21%, of which the third quarter revenue and net profit were both Decline; R&D expenses were 4.
142 billion yuan, a year-on-year increase of 23.
85%, accounting for more than 20% of revenue
.

(Announcement of listed companies)

View:

View:

The performance is under pressure under centralized procurement and PD-1 internal volume, and Hengrui Pharmaceuticals is facing the challenge
.

With the internal reform of the pharmaceutical industry and the intensification of international competition, domestic pharmaceutical companies are generally facing challenges.

Microchip's second category 1 new drug was approved

Microchip's second category 1 new drug was approved

On October 19, the official website of the State Food and Drug Administration showed that the first class of new drug Sieglipta Sodium Tablets independently developed by Microchip was approved for marketing.
It took more than 16 years from the first clinical approval to the approval for marketing
.

Sieglipta is a nuclear receptor peroxisome proliferative receptor (PPAR) full activator.

Data within meters:

Data within meters:

In the chemical drug terminal of public medical institutions in China, diabetes drugs are the therapeutic subcategory with the largest sales among digestive system and metabolic drugs.
In 2021, the H1 market will exceed 25 billion yuan, and the market share of insulin and similar drugs and non-insulin hypoglycemic drugs Similar
.

4 billion market! The results of 50 drug collections are released

4 billion market! The results of 50 drug collections are released

On October 19th, the results of the planned selection of the second batch of medicines in Shandong Province (Lu-Jin Alliance) for centralized and large-volume procurement were announced
.

The drug market size of this centralized procurement covering Shandong and Shanxi provinces reached 3.

Further reading:

Further reading:

The biggest price drop was the Ozagrel Sodium Injection from Dandong Medical Innovation Pharmaceutical Co.
, Ltd.
, which dropped from 16.
52 yuan/bottle to 1.
2 yuan/bottle, a 92.
74% reduction; the largest price reduction was Tianma Tianji Bio-de Tely for Injection Vasopressin was reduced from 315.
8 yuan/piece to 37.
8 yuan/piece, and the price of a single piece was reduced by 278 yuan
.

2 blockbuster biological drugs welcome the first domestically declared company

2 blockbuster biological drugs welcome the first domestically declared company

On October 22, Taizhou Maibotek Pharmaceutical's application for injection CMAB007 (omalizumab biosimilar) submitted by the new drug category 3.
4 was accepted by the CDE.
US$3 billion; On October 19th, Chia Tai Tianqing Pharmaceutical Nanjing Shunxin Pharmaceutical was accepted by the CDE for its clinical application for mepolizumab injection submitted with a new drug category 3.
3.
Up to 994 million pounds
.

(Compiled by Mi Nei Net)

2.
6 billion debts, well-known pharmaceutical companies will change owners

2.
6 billion debts, well-known pharmaceutical companies will change owners

On October 21, Zixin Pharmaceutical announced that the company’s controlling shareholder Kangping Investment and Sinopharm Zhaoxiang signed a "voting entrustment agreement", and Sinopharm Zhaoxiang will become the company’s controlling shareholder and obtain control of the company
.

Zixin Pharmaceutical stated that Sinopharm Zhaoxiang has a background in state-owned assets and traditional Chinese medicine industry, which will help the company to overcome the current operating dilemma caused by the debt crisis.
Diversified support to improve the asset quality of listed companies and promote the company's sustained and rapid development
.
(Announcement of listed companies)

Data within meters:

Data within meters:

Zixin Pharmaceutical’s owner operates the proprietary Chinese medicine, ginseng, gene sequencer and supporting reagent industries.
Affected by factors such as the unfavorable environment in the pharmaceutical industry and the epidemic, the company’s main business has been severely affected and operating funds are tight
.
As of September 15, the total amount of overdue debts of Zixin Pharmaceutical and its subsidiaries was approximately 2.
623 billion yuan
.

45 varieties are included in the quantity procurement

45 varieties are included in the quantity procurement

On October 22, the Anhui Province Pharmaceutical Centralized Procurement Platform issued an announcement to include 45 varieties in mass procurement, divided into groups A and B for comprehensive bidding, with a technical review score × 40% + price review score
.
45 varieties of injection 37, comprising piperacillin sodium and sulbactam sodium (4: 1) injection, propofol injection, injection triptorelin acetate, mezlocillin sodium injections
.
(Pharmaceutical Centralized Procurement Platform in Anhui Province)

Huadong Medicine introduces 8 new drugs under development

Huadong Medicine introduces 8 new drugs under development

On October 19, Huadong Medicine announced that the company’s wholly-owned subsidiary Sino-American Huadong and Huadong Medicine Investment Holdings signed an equity investment agreement and product exclusive license agreement with Ashvattha
.
Huadong Pharmaceutical Investment Holdings will invest in phases to subscribe for the Series B preferred shares issued by Ashvattha
.
At the same time, Sino-US East China will obtain exclusive licenses for 8 products under development owned by Ashvattha in 20 Asian countries and regions
.
(Company official website)

Further reading:

Further reading:

Ashvattha is an innovative biopharmaceutical company specializing in hydroxy dendrimer therapies (HDTs)
.
The 8 products under development introduced by Huadong Medicine this time cover the treatment of tumors, metabolic comorbidities, inflammation and other diseases.
Among them, one product has started phase II clinical trials in the United States, and two products are scheduled to submit IND applications in Q1 of 2022
.

104 generic drugs announced reference preparations

104 generic drugs announced reference preparations

On October 20th, the State Food and Drug Administration announced the announcement of two generic drug reference preparation catalogues (forty-sixth batch) and (forty-seventh batch)
.
A total of 104 generic drug reference preparations were included in the two batches, most of which were non-imported original research drugs, domestically marketed original research drugs, and American Orange Book varieties
.
(National Food and Drug Administration)

A large number of drug purchases "stopped"

A large number of drug purchases "stopped"

On October 21, the Jiangxi Province Pharmaceutical Purchasing Service Platform issued a notice that 164 drugs (all injections) failed to pass the consistency evaluation and 3 other companies had passed the consistency evaluation, and their online procurement qualifications were suspended; October 19 On the day, the Shaanxi Provincial Public Resources Trading Center issued a notice stating that 797 drugs were removed from the Internet, mainly due to the fact that there were more than three listed drugs, different packaging of the selected varieties, repeated reviews with new applications, and no quotations
.
(Compiled by Mi Nei Net)

Merck’s exclusive best-selling drug is out of stock

Merck’s exclusive best-selling drug is out of stock

On October 19, CCTV Finance reported that "Sining" (carzodopa sustained-release tablets), a commonly used drug for Parkinson's syndrome, was out of stock on the market recently, and many patients and their families reported that they could not buy the drug in the hospital.
, Can only be purchased online at a price that is 10 or even 20 times higher than the price of medical insurance
.
(Health and Knowledge Bureau)

Corporate response:

Corporate response:

"Xining" is produced abroad and packaged in China.
Due to the epidemic, raw materials are in short supply, and the output is reduced
.
At present, the company is working closely with government departments to restore the normal supply of "Xining" as soon as possible to meet the medication needs of the majority of patients
.

16 drugs were investigated

16 drugs were investigated

On October 22, the Liaoning Provincial Drug and Medical Consumables Centralized Purchasing Network issued a notice that due to price and supply abnormalities, three drugs including dacarbazine for injection, sodium nitroprusside for injection, and lobeline hydrochloride injection require further investigation; on the same day, In order to ensure the supply of medicines to medical institutions, the province initiated investigations into 13 online medicines, including aminomethylbenzoic acid injection, propranolol hydrochloride tablets, and digoxin oral solution, involving 26 production (agent) companies
.
(Liaoning Province Medicines and Medical Consumables Centralized Procurement Network)